evenfolio

Healthcare · NSE: HCG

Healthcare Global Enterprises

Q2 FY27 earnings and concall highlights

Price as of 16 Nov 2026
568.20−0.83%

Q2 FY27 earnings call · Guided by management

Call held 6 Nov 2026 · Read the filing on NSEFiling

30–35​%Tax rate · near termKumar · Q&A · p. 12
4–5​%MVT share of revenue · MVT · this yearMattoo · Q&A · p. 14
1,279​INR millionCapex · H1 FY27Kumar · p. 6
25​bedsOperational beds added · Q2 FY27Mattoo · p. 4
M.Cap
₹8,483Cr
P/E
750.7×
1Y return
−23.20%
From 52W high
−26.7%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue732647+13.1%695+5.3%
EBITDA133123+8.2%122+9.1%
EBITDA margin18.2%19.1%-83 bps17.6%+64 bps
One-off items-12————
PBTProfit before tax1720-10.4%24-27.4%
Net profit516-70.6%14-65.2%
EPS (₹)0.321.16-72.4%0.92-65.2%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.

Guidance

North Bengaluru hospital: North Bengaluru hospital to reach monthly EBITDA breakeven by end of Q4 FY27

Manish Mattoo · Executive Director and CEO · Q&A · p. 7
“As stated earlier also, we are on track to hit monthly EBITDA breakeven by end of Q4 of this financial year. There is no change there.”

Guidance of mid-teens revenue growth and high teens to 20% EBITDA growth kept

Manish Mattoo · Executive Director and CEO · Q&A · p. 7
“Sumit, our guidance has been around mid-teens growth, coupled by high teens to 20% EBITDA growth, and we continue to stay on track as far as that is concerned.”

Guidance is organic; any acquisition would add to growth

Manish Mattoo · Executive Director and CEO · Q&A · p. 7
“Of course, if there is any inorganic opportunity over and above this is all, of course, organic growth.”

Gujarat: Gujarat expected back to mid-teens growth by Q4 FY27

Manish Mattoo · Executive Director and CEO · Q&A · p. 7
“I think Gujarat should be back to the mid-teens growth by Q4 of this year. That is what we are anticipating.”

North Bengaluru hospital: North Bengaluru expected to break even in January-March quarter

Sanjeev Kumar · Chief Financial Officer · Q&A · p. 9
“So, between January to March quarter, we will be expected to be break-even.”

More figures from the call

Company · Capacity
146​bedsBeds operationalised · H1 FY27
“we have operationalized a total of 146 beds in H1 FY 2027”
Manish Mattoo · Executive Director and CEOp. 4

In short

  1. 01Q2 FY27 revenue was INR 7,318 million, up 16% year-on-year.
  2. 02Q2 EBITDA was INR 1,425 million, up 17%, with margin at 19.7%.
  3. 03Trade margin cap on cancer drugs seen to cut EBITDA by mid-to-high single digit % annualised, from Q3.
  4. 04Guidance of mid-teens revenue growth and high teens to 20% EBITDA growth kept.
  5. 05Mid-teen revenue and high teens EBITDA growth expected for FY28 and FY29.
  6. 06North Bengaluru hospital on track for monthly EBITDA breakeven by end of Q4 FY27.
  7. 07Exceptional EPCG provision of INR 116 million; no further material provisions expected.
  8. 08Net debt excluding capital leases was INR 5,751 million at 30 September 2026.

Capex

MR-LINAC radiation therapy system started at North Bengaluru hospital

Manish Mattoo · Executive Director and CEO · p. 4
“we operationalized the MR-LINAC, a highly advanced adaptive radiation therapy system at our North Bengaluru hospital”

Ahmedabad: Cardiac surgical robotic system added at Ahmedabad multi-specialty hospital

Manish Mattoo · Executive Director and CEO · p. 4
“added a cardiac surgical robotic system at our multi-specialty hospital in Ahmedabad”

Segments

South cluster: South cluster revenue INR 2,941 million, up 18%, 40% of revenue

Manish Mattoo · Executive Director and CEO · p. 3
“Starting with the South cluster, the revenue stood at INR 2,941 million. Delivering a strong growth of 18% and contributing to 40% of our overall revenue.”

South cluster: South cluster ARPP up 14%, patient volumes up 4%

Manish Mattoo · Executive Director and CEO · p. 3
“Growth was supported by a 14% improvement in ARPP and a 4% increase in patient volumes”

West cluster: West cluster revenue INR 3,147 million, up 10%, 43% of revenue

Manish Mattoo · Executive Director and CEO · p. 3
“Revenue stood at INR 3,147 million, registering 10% year-on-year growth and contributing 43% to overall revenue.”

Maharashtra: Maharashtra grew at mid-teens on payor mix shift

Manish Mattoo · Executive Director and CEO · p. 4
“The Maharashtra region delivered a strong performance with a mid-teens growth, driven by healthy patient demand and improved realization, led by a favorable payor mix shift.”

Gujarat: Gujarat growth slower due to deliberate cut in institutional mix

Manish Mattoo · Executive Director and CEO · p. 4
“This was partially offset by relatively moderated growth across our Gujarat centers, largely on account of deliberate rationalization of institutional mix to improve profitability.”

Demand

Demand for quality cancer care in India seen staying robust for years

Manish Mattoo · Executive Director and CEO · Q&A · p. 8
“I think the inherent demand in the system and need for high-quality care in India will remain to be robust for many years to come, and we are very positive about that.”

Rising cancer incidence, screening and affordability support demand

Manish Mattoo · Executive Director and CEO · p. 5
“Rising cancer incidence, along with improved screening and affordability, is continuing to support sustained demand for high-quality cancer care.”

Margins and costs

Q2 EBITDA INR 1,425 million, up 17%; margin 19.7% vs 19.2% a year ago

Manish Mattoo · Executive Director and CEO · p. 3
“EBITDA for the quarter, including North Bengaluru loss of INR 61 million, was INR 1,425 million, representing growth of 17% year-on-year, with EBITDA margins improved to 19.7% compared to 19.2% in Q2FY26.”

About INR 60 million extra employee cost from Karnataka wage revision in Q2

Manish Mattoo · Executive Director and CEO · p. 3
“margin expansion during the quarter was partly moderated due to incremental employee cost amounting to approximately INR 60 million on account of revision in Karnataka Wage Act 2026.”

Excluding wage revision, Q2 EBITDA growth was over 20%

Manish Mattoo · Executive Director and CEO · p. 3
“excluding the wage revision impact, EBITDA growth was over 20% year-on-year.”

H1 adjusted EBITDA margin up 84 bps to 19.7% from 18.8%

Sanjeev Kumar · Chief Financial Officer · p. 5
“Adjusted EBITDA margin improved by 84 basis points to 19.7% compared with 18.8% in H1 FY 2026”

H1 depreciation INR 1,365 million vs INR 1,176 million a year ago

Sanjeev Kumar · Chief Financial Officer · p. 5
“Depreciation and amortization expenses for H1 FY 2027 stood at INR 1,365 million as compared with INR 1,176 million in the corresponding period last year”

Debt and working capital

H1 finance costs down 11% to INR 775 million after INR 1,700 million debt repaid

Sanjeev Kumar · Chief Financial Officer · p. 5
“Finance costs declined by 11% year-on-year to INR 775 million as compared to INR 876 million in H1 FY 2026, supported by debt repayments of INR 1,700 million during the first half of this year.”

Net debt excluding capital leases INR 5,751 million at 30 September 2026

Sanjeev Kumar · Chief Financial Officer · p. 6
“Net debt excluding capital leases stood at INR 5,751 million as of September 30, 2026.”

INR 170 crore repaid to banks

Sanjeev Kumar · Chief Financial Officer · Q&A · p. 9
“We also repaid INR 170 crore to the banks as part of our debt repayment.”

H1 CFO to EBITDA conversion about 54% vs 80%+ a year ago

Sanjeev Kumar · Chief Financial Officer · Q&A · p. 11
“you are right, CFO to EBITDA conversion is approximately 54% as compared to 80% + in last year's same quarter”

About INR 35 crore from AP Government Aarogyasri scheme shown as borrowings

Sanjeev Kumar · Chief Financial Officer · Q&A · p. 11
“One is that we got almost INR 35 crore from the AP Government under the Aarogyasri scheme, which is being shown as part of the borrowings at this point of time.”

Fund raising

Rights proceeds used: INR 150 crore Vizag, INR 170 crore debt, INR 100 crore general

Ravi Gothwal · Head of Investor Relations · Q&A · p. 9
“So, INR 150 crore, like Sanjeev mentioned, was towards MG Vizag acquisition, INR 170 crore towards debt repayment, and another INR 100 crore for the general corporate purposes.”

Rights issue raised about INR 400 crore earlier

Sanjeev Kumar · Chief Financial Officer · Q&A · p. 12
“we had raised a Right issue earlier, which was amounted to almost INR 400 crore, and this INR 150 crore was used out of the proceeds of the right issue.”

Acquisitions and new business

Vizag: Bought further 34% of Vizag operations for about INR 150-160 crore

Sanjeev Kumar · Chief Financial Officer · Q&A · p. 9
“One is the fact that we acquired an additional 34% in our Vizag operations, and we used almost INR 150 crore-INR 160 crore in that acquisition.”

Milann Fertility: Milann Fertility business divested in June 2026; figures exclude it

Manish Mattoo · Executive Director and CEO · p. 2
“exclude the Milann Fertility business, which was divested in June 2026.”

First CAR T-cell therapy at Ahmedabad; new robotic surgeries at three centres

Manish Mattoo · Executive Director and CEO · p. 4
“On the clinical front, key milestones included the first CAR T-cell therapy at HCG Ahmedabad, the introduction of a robotic breast surgical system at KR Road, Bengaluru, robotic spine surgery at HCG Rajkot, and transoral robotic surgery at HCG Vadodara.”

KR Hospital, Bengaluru: Launched 1,212-gene liquid biopsy panel and two nuclear medicine tracers

Manish Mattoo · Executive Director and CEO · p. 4
“We also launched a 1,212-gene liquid biopsy panel and introduced two new nuclear medicine tracers at KR Hospital, Bengaluru, enhancing our precision diagnostics capabilities.”

One-offs

Non-cash ESOP expense of INR 29.8 million in the quarter

Sanjeev Kumar · Chief Financial Officer · p. 5
“we also recognized an ESOP expense of INR 29.8 million arising from the grant of ESOPs in September 2026. Please note that this is a non-cash expense.”

Exceptional expense of INR 116 million for EPCG provision

Sanjeev Kumar · Chief Financial Officer · Q&A · p. 6
“We recognize an exceptional expense of INR 116 million towards provisioning related to the EPCG.”

No further material EPCG provisions expected in near term

Sanjeev Kumar · Chief Financial Officer · Q&A · p. 6
“Accordingly, we do not anticipate any further material provisions in the near term.”

No cash impact so far from EPCG provision

Sanjeev Kumar · Chief Financial Officer · Q&A · p. 6
“At present, there is no cash impact as of now.”

MVT: MVT international revenue counts as export earning for EPCG

Sanjeev Kumar · Chief Financial Officer · Q&A · p. 13
“So, the international revenue which comes through the MVT process is counted as export earning.”

Risks

Trade margin cap on cancer drugs seen to cut EBITDA by mid-to-high single digit %

Manish Mattoo · Executive Director and CEO · p. 5
“Based on our assessment on an absolute basis, we estimate a mid-to-high single-digit percentage impact to EBITDA on an annualized basis.”

medical oncology: 137 capped drugs are a small part of the oncology portfolio

Manish Mattoo · Executive Director and CEO · Q&A · p. 6
“these 137 drugs which came under the capping represent a small subset of the overall oncology portfolio”

Most drugs used are now under the 30% trade margin cap

Manish Mattoo · Executive Director and CEO · Q&A · p. 8
“I think majority of the drugs are under the trade margin cap now, barring, I think, immunotherapy, where the margins in any case are lower than the 30% cap.”

Trade margin cap impact to show from Q3, effective November

Manish Mattoo · Executive Director and CEO · Q&A · p. 8
“The impact, whatever impact we see will be only seen from Q3 onwards, because this is effective November.”

Payor mix changes may lower volumes in some markets and quarters

Manish Mattoo · Executive Director and CEO · Q&A · p. 11
“But yes, I mean, in some markets, in some quarters, it may result in moderation of the volumes.”

Other

Q2 FY27 revenue INR 7,318 million, up 16% year-on-year

Manish Mattoo · Executive Director and CEO · p. 2
“In Quarter 2 FY 2027, HCG delivered revenue of INR 7,318 million, representing a growth of 16% year- on- year.”

Q2 growth driven by 9% rise in patient volumes; revenue per patient up 7%

Manish Mattoo · Executive Director and CEO · p. 3
“primarily driven by a 9% increase in patient volumes, while average revenue per patient increased by 7%”

Robotic surgeries up 37% year-on-year

Manish Mattoo · Executive Director and CEO · p. 3
“This included a 37% year-on-year increase in robotic surgeries”

non-institutional: Non-institutional revenue up 21%; its share of revenue rose over 300 bps to 69%

Manish Mattoo · Executive Director and CEO · p. 3
“with non-institutional revenue growing by 21% year-on-year, resulting in an improvement of over 300 basis points in its revenue share to 69%.”

H1 FY27 revenue INR 14,100 million, up 15%

Sanjeev Kumar · Chief Financial Officer · p. 5
“Consolidated revenue for H1 FY 2027 stood at INR 14,100 million, representing growth of 15% year-on-year basis.”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools